Camille N Kotton1. 1. Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: Cytomegalovirus (CMV) is the most common infection after organ transplant. In addition to causing a viral syndrome and infection, it also increases the risk for complications in the organ transplant, along with higher overall morbidity and mortality. Prevention and ideal treatment of CMV is paramount for optimal outcomes, both for individuals as well as for transplant programs. New guidelines and novel therapies are changing the way we manage disease. RECENT FINDINGS: Several new antiviral agents have emerged in recent times, including letermovir, maribavir, and brincidofovir, enhancing our ability to prevent and treat CMV. Recent data on novel agents will be reviewed, with an emphasis on recent guidelines and best practices. SUMMARY: Optimal treatment, influenced by recent advances in the field, including management of resistant virus, results in better outcomes with this significant and virulent virus.
PURPOSE OF REVIEW: Cytomegalovirus (CMV) is the most common infection after organ transplant. In addition to causing a viral syndrome and infection, it also increases the risk for complications in the organ transplant, along with higher overall morbidity and mortality. Prevention and ideal treatment of CMV is paramount for optimal outcomes, both for individuals as well as for transplant programs. New guidelines and novel therapies are changing the way we manage disease. RECENT FINDINGS: Several new antiviral agents have emerged in recent times, including letermovir, maribavir, and brincidofovir, enhancing our ability to prevent and treat CMV. Recent data on novel agents will be reviewed, with an emphasis on recent guidelines and best practices. SUMMARY: Optimal treatment, influenced by recent advances in the field, including management of resistant virus, results in better outcomes with this significant and virulent virus.
Authors: Julius Müller; Rachel Tanner; Magali Matsumiya; Margaret A Snowden; Bernard Landry; Iman Satti; Stephanie A Harris; Matthew K O'Shea; Lisa Stockdale; Leanne Marsay; Agnieszka Chomka; Rachel Harrington-Kandt; Zita-Rose Manjaly Thomas; Vivek Naranbhai; Elena Stylianou; Stanley Kimbung Mbandi; Mark Hatherill; Gregory Hussey; Hassan Mahomed; Michele Tameris; J Bruce McClain; Thomas G Evans; Willem A Hanekom; Thomas J Scriba; Helen McShane; Helen A Fletcher Journal: JCI Insight Date: 2019-12-05
Authors: Margaret R Jorgenson; Jillian L Descourouez; Cynthia Wong; Jill R Strayer; Sandesh Parajuli; John P Rice; Robert R Redfield; Jeannina A Smith; Didier A Mandelbrot; Christopher M Saddler Journal: Transpl Infect Dis Date: 2021-03-15
Authors: Iris N Pardieck; Suzanne van Duikeren; Dominique M B Veerkamp; Dena J Brasem; Anke Redeker; Jeroen van Bergen; Wanda Han; Ferry Ossendorp; Gerben Zondag; Ramon Arens Journal: Front Immunol Date: 2022-01-27 Impact factor: 7.561